期刊文献+

急性髓系白血病免疫治疗的研究进展与展望 被引量:8

Advances and prospects of research on immunotherapy of acute myeloid leukemia
下载PDF
导出
摘要 大多数急性髓系白血病(acute myeloid leukemia,AML)患者化疗诱导缓解后不可避免地面临复发。异基因造血干细胞移植作为AML最有效的治疗,通过免疫介导的移植物抗白血病效应根除白血病细胞,能有效预防AML复发。移植技术和单倍体移植模式进展使得"人人都能进行造血干细胞移植"。靶向治疗,如基因工程T细胞(嵌合抗原受体T细胞)、单克隆抗体、新型双特异性单抗,能特异性杀伤表达特殊抗原的白血病细胞,而不伤害正常细胞,将成为AML免疫治疗的新策略。研究发现高表达于急性单核细胞白血病细胞的新抗原急性单核细胞白血病相关抗原-34(monocytic leukemia associated antigen-34,MLAA-34)具有抗白血病细胞凋亡作用,且MLAA-34多肽可诱导特异性CTL杀伤活性,具有较强的免疫原性,MLAA-34可作为急性单核细胞白血病免疫治疗新的理想靶抗原。总之,新近进展有价值的免疫治疗白血病相关抗原的鉴定有可能根除化疗后白血病微小残留病变,有望降低AML复发,延长AML患者生存。 Relapse after chemotherapy is inevitable in the majority of patients with acute myeloid leukemia(AML).Allogeneic hemopoeitic stem cell transplantation is the most effective treatment of AML.Following transplant,recipient AML cells are eradicated by donor immune cells through the graft-versus-leukemia(GVL)effect which is effective for the prevention of relapse.The new era emerges as"everyone has a donor for hematopoietic stem cell transplantation"due to progress in transplant technology and haploid transplantation model.Targeted therapies,such as genetically engineered T cells(chimeric antigen receptor T cells),monoclonal antibodies,and bispecific T-cell engagers,can specifically kill leukemia cells that express particular antigens,but do not damage normal cells,which will be new immunotherapeutic strategies for AML.It has been found that monocytic leukemia associated antigen-34(MLAA-34)is upregulated in acute monocytic leukemia cells and is a novel anti-apoptotic factor related closely to acute monocytic leukemia.MLAA-34 peptide can induce specific CTL killing activity and has a strong immunogenicity.MLAA-34 is a new promising new target antigen for therapeutic applications in AML.In short,recent advances in immunology and identification of promising leukemia-associated antigens open the possibilities for eradicating minimal residual diseases by antigen-specific immunotherapy after chemotherapy.Such progress will establish immunotherapy as an important armament to combat AML relapse and improve overall survival of AML patients.
作者 张王刚 白菊
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2015年第5期573-579,共7页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 陕西省科技统筹创新工程计划资助项目(No.2014KTCL03-01 2012KTCL03-11)~~
关键词 急性髓系白血病 造血干细胞移植 嵌合抗原受体T细胞 单克隆抗体 新型双特异性单抗 急性单核细胞白血病相关抗原-34 acute myeloid leukemia hematopoietic stem cell transplantation chimeric antigen receptor T cell monoclonal antibody novel bi-specific T-cell engager acute monocytic leukemia associated antigen-34
  • 相关文献

参考文献45

  • 1ZHAO J, HE A, ZHANG W, et al. Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute mono- cytic leukemia~J]. Cancer Immunol Immunother, 2011, 60 (4) :587-597. 被引量:1
  • 2ZHANG PY, ZHANG WG, HE AL, et al. Identification and functional characterization of the novel acute monocytic leuke- mia associated antigen MLAA-34[J]. Cancer Immunol Immu- nother, 2009, 58(2):281-290. 被引量:1
  • 3ZHANG WJ, ZHANG WG, ZHANG PY, et al. The expres- sion and functional characterization associated with cell apopto- sis and proteomic analysis of the novel gene MLAA-34 in U937 cells[J]. Oncol Rep, 2013, 29(2):491-506. 被引量:1
  • 4YAHNG SA, KIM JH, JEON YW, et al. A well-tolerated reg- imen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable en- graftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia[J]. Biol Blood Marrow Transplant, 2015, 21 (1): 119-129. 被引量:1
  • 5LUZNIK L, FUCHS EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation[J]. Cancer Control, 2002, 9 (2) : 123- 137. 被引量:1
  • 6YEGIN ZA, OZKURT ZN, AKI SZ, et al. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantationEJ]. Transfus Apher Sci, 2010, 42(3) :239-245. 被引量:1
  • 7HUANG XJ, LIU DH, LIU KY, et al. Donor lymphocyte in- fusion for the treatment of leukemia relapse after HLA-mis- matched/haploidentical T-cell-replete hematopoietic stem cell transplantation[J]. Haematologica, 2007, 92(3):414-417. 被引量:1
  • 8张毅,Michael Nishimura.肿瘤的细胞免疫治疗[J].郑州大学学报(医学版),2011,46(2):165-169. 被引量:9
  • 9OCHI T, FUJIWARA H, OKAMOTO S, et al. Novel adoptive T-cell immunotherapy using a WTI-specific TCR vector enco- ding silencers for endogenous TCRs shows marked antileukemia reactivity and safety[J]. Blood, 2011, 118(6):1495-1503. 被引量:1
  • 10MAUDE SL, FREY N, SHAW PA, et al. Chimeric antigen re- ceptor T cells for sustained remissions in leukemia~-J~. N Engl J Med, 2014, 371(16) :1507-1517. 被引量:1

二级参考文献41

  • 1Michael R. Verneris,Martin Kornacker,Volker Mail?nder,Robert S. Negrin.Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis[J]. Cancer Immunology, Immunotherapy . 2000 (6) 被引量:1
  • 2Richard L. Kradin,Lenora A. Boyle,Frederic I. Preffer,Ronald J. Callahan,Martha Barlai-Kovach,H. William Strauss,Steven Dubinett,James T. Kurnick.Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer[J]. Cancer Immunology Immunotherapy . 1987 (1) 被引量:1
  • 3Frankel TL,Burns WR,Peng PD,et al.Both CD4and CD8T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosi-nase. J Immunol . 2010 被引量:1
  • 4Koya RC,Mok S,Comin-Anduix B,et al.Kinetic phases of distribution and tumor targeting by T cell receptor engi-neered lymphocytes inducing robust antitumor responses. Proceedings of the National Academy of Sciences of the United States of America . 2010 被引量:1
  • 5Duval L,Schmidt H,Kaltoft K,et al.Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2restricted MART-1T-cell receptor:a phaseⅠtrial in meta-static melanoma. Clinical Cancer Research . 2006 被引量:1
  • 6Warren EH,Fujii N,Akatsuka Y,et al.Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantationwith T cells specific for minor histocompatibility antigens. Blood . 2010 被引量:1
  • 7Khammari A,Labarrire N,Vignard V,et al.Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. Journal of Investigative Dermatology . 2009 被引量:1
  • 8Casalegno-Garduo R,Schmitt A,Yao J,et al.Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer Immunology Immunotherapy . 2010 被引量:1
  • 9Geldmacher A,Freier A,Losch FO,et al.Therapeutic vac-cination for cancer immunotherapy:antigen selection and clinical responses. Hum Vaccin . 2011 被引量:1
  • 10Vergati M,Intrivici C,Huen NY,et al.Strategies for cancer vaccine development. Journal of Biomedicine and Biotechnology . 2010 被引量:1

共引文献8

同被引文献91

引证文献8

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部